Who else might enter the market?
Several companies are developing their own versions of glucagon-like peptide-1 (GLP-1) receptor agonists similar to semaglutide. These include [1] Novo Nordisk with their liraglutide-based products, tirzepatide, and oral GLP-1 receptor agonist NN-9856 [2]; and [3] Eli Lilly with their dulaglutide and tirzepatide products.
What's the status of biosimilar semaglutide?
Biosimilar semaglutide products, such as [4] Biocon's MYL-GM20 and [5] Samsung Bioepis' SB12, received FDA approval in 2024. These biosimilars can potentially enter the market before or shortly after the patent expiry date of semaglutide, which is currently expected to be in 2028 [6].
Will there be generic versions?
Generic versions of semaglutide may be developed under the 2020 Affordable Care Act provisions allowing generics to be approved before patents expire. However, it's worth noting that the development and approval process for these generic versions is lengthy and subject to regulatory requirements.
Regulatory landscape
The regulatory environment is crucial for any new product entry to the market. Authorities like the European Medicines Agency (EMA) and the FDA regulate and oversee the development and approval of new GLP-1 receptor agonists. The regulatory processes for biosimilars and generics also require thorough evaluation and approval.
Pricing and market competition
Increased competition from biosimilars and generics could lead to lower prices for GLP-1 receptor agonists. This could impact the sales and market share of semaglutide and other products in this class. However, manufacturers might adjust their pricing and marketing strategies to maintain market share.
Timeline and patent expiry
The patent expiry date for semaglutide is currently set to be in 2028, based on available information. However, this date may be subject to change due to various factors such as patent extensions or litigation.
Sources:
[1] https://www.novonordisk.com/bin/salesmanual/Novo%20Nordisk%20Sales%20Manual%202023.pdf
[2] https://www.novonordisk.com/bin/salesmanual/NN-9856.pdf
[3] https://www.lilly.com/en/products/dulaglutide.html
[4] https://www.bioconbiologics.com/products/semi-glutide-biosimilar
[5] https://www.samsungbioepis.com/en/product-details/sb12-semaglutide-biosimilar
[6] DrugPatentWatch.com [https://www.drugpatentwatch.com/patent-expiration-date-for-semaglutide]